Virax Biolabs Group Ltd
NASDAQ:VRAX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Azucar Minerals Ltd
OTC:AXDDF
|
CA |
Virax Biolabs Group Ltd
PP&E Gross
Virax Biolabs Group Ltd
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Virax Biolabs Group Ltd
NASDAQ:VRAX
|
PP&E Gross
$1.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Virax Biolabs Group Ltd
Glance View
Virax Biolabs Group Ltd is a GB-based company operating in Health Care Providers & Services industry. Virax Biolabs Group Limited is a biotechnology company. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and med-tech and personal protective equipment (PPE) products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear, ViraxCare, and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Its products include antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody tests. ViraxCare develops and distributes advanced medical devices, technology, and PPE globally. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus.
See Also
What is Virax Biolabs Group Ltd's PP&E Gross?
PP&E Gross
1.5m
USD
Based on the financial report for Mar 31, 2025, Virax Biolabs Group Ltd's PP&E Gross amounts to 1.5m USD.
What is Virax Biolabs Group Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 1Y
39%
Over the last year, the PP&E Gross growth was 39%.
